CR20230482A - Composiciones y métodos para inhibir cetohexoquinasa (khk) - Google Patents
Composiciones y métodos para inhibir cetohexoquinasa (khk)Info
- Publication number
- CR20230482A CR20230482A CR20230482A CR20230482A CR20230482A CR 20230482 A CR20230482 A CR 20230482A CR 20230482 A CR20230482 A CR 20230482A CR 20230482 A CR20230482 A CR 20230482A CR 20230482 A CR20230482 A CR 20230482A
- Authority
- CR
- Costa Rica
- Prior art keywords
- khk
- compositions
- methods
- ketohexokinase
- inhibiting
- Prior art date
Links
- 102100023418 Ketohexokinase Human genes 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 108010062852 Ketohexokinase Proteins 0.000 title 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163173775P | 2021-04-12 | 2021-04-12 | |
| US202163182277P | 2021-04-30 | 2021-04-30 | |
| EP21196784 | 2021-09-15 | ||
| PCT/EP2022/059663 WO2022218941A2 (en) | 2021-04-12 | 2022-04-11 | Compositions and methods for inhibiting ketohexokinase (khk) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20230482A true CR20230482A (es) | 2023-12-07 |
Family
ID=81448852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20230482A CR20230482A (es) | 2021-04-12 | 2022-04-11 | Composiciones y métodos para inhibir cetohexoquinasa (khk) |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20220340909A1 (https=) |
| EP (1) | EP4323518A2 (https=) |
| JP (1) | JP2024516356A (https=) |
| KR (1) | KR20230170732A (https=) |
| CN (1) | CN117120612A (https=) |
| AU (1) | AU2022256742A1 (https=) |
| BR (1) | BR112023017367A2 (https=) |
| CA (1) | CA3214439A1 (https=) |
| CL (1) | CL2023003017A1 (https=) |
| CO (1) | CO2023013465A2 (https=) |
| CR (1) | CR20230482A (https=) |
| DO (1) | DOP2023000223A (https=) |
| EC (1) | ECSP23076906A (https=) |
| IL (1) | IL307315A (https=) |
| JO (1) | JOP20230250A1 (https=) |
| MX (1) | MX2023012048A (https=) |
| PE (1) | PE20250400A1 (https=) |
| PH (1) | PH12023552830A1 (https=) |
| TW (1) | TW202305135A (https=) |
| WO (1) | WO2022218941A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022226098A1 (en) * | 2021-02-26 | 2023-08-24 | Alnylam Pharmaceuticals, Inc. | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| TW202430192A (zh) | 2022-10-11 | 2024-08-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療nash之劑量方案 |
| TW202430191A (zh) | 2022-10-11 | 2024-08-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療伴有晚期纖維化及/或硬化之nash的方法 |
| WO2024175062A1 (zh) * | 2023-02-23 | 2024-08-29 | 大睿生物医药科技(上海)有限公司 | 调控KHK基因活性的dsRNA分子 |
| WO2024260379A1 (zh) * | 2023-06-20 | 2024-12-26 | 施能康医药科技(苏州)有限公司 | 靶向已酮糖激酶的核酸及其用途 |
| CN117925620B (zh) * | 2024-01-30 | 2024-09-03 | 大连医科大学 | 一种果糖激酶khk的小干扰和短发夹rna序列组合及其应用 |
| WO2025184876A1 (zh) * | 2024-03-07 | 2025-09-12 | 竣莅医药科技（无锡）有限公司 | 一种rna干扰触发分子与对应核酸干扰药物制剂及其用途 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6469158B1 (en) | 1992-05-14 | 2002-10-22 | Ribozyme Pharmaceuticals, Incorporated | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
| US5977343A (en) | 1992-05-14 | 1999-11-02 | Ribozyme Pharmaceuticals, Inc. | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
| US5804683A (en) | 1992-05-14 | 1998-09-08 | Ribozyme Pharmaceuticals, Inc. | Deprotection of RNA with alkylamine |
| ATE227342T1 (de) | 1993-09-02 | 2002-11-15 | Ribozyme Pharm Inc | Enzymatische nukleiksaüre die nicht-nukleotide enthaltet |
| US5889136A (en) | 1995-06-09 | 1999-03-30 | The Regents Of The University Of Colorado | Orthoester protecting groups in RNA synthesis |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| US6111086A (en) | 1998-02-27 | 2000-08-29 | Scaringe; Stephen A. | Orthoester protecting groups |
| ES2336887T5 (es) | 2000-03-30 | 2019-03-06 | Whitehead Inst Biomedical Res | Mediadores de interferencia por ARN específicos de secuencias de ARN |
| CA2429814C (en) | 2000-12-01 | 2014-02-18 | Thomas Tuschl | Rna interference mediating small rna molecules |
| US20050159378A1 (en) | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA) |
| WO2003040395A2 (en) | 2001-11-07 | 2003-05-15 | Applera Corporation | Universal nucleotides for nucleic acid analysis |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| WO2007030167A1 (en) | 2005-09-02 | 2007-03-15 | Nastech Pharmaceutical Company Inc. | Modification of double-stranded ribonucleic acid molecules |
| DK2341943T3 (en) | 2008-09-22 | 2019-02-25 | Dicerna Pharmaceuticals Inc | COMPOSITIONS AND METHODS OF SPECIFIC INHIBITION OF DSRNA REPRINT WITH MODIFICATIONS |
| KR101728655B1 (ko) | 2008-12-18 | 2017-04-19 | 다이서나 파마수이티컬, 인크. | 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법 |
| US20100249214A1 (en) | 2009-02-11 | 2010-09-30 | Dicerna Pharmaceuticals | Multiplex dicer substrate rna interference molecules having joining sequences |
| WO2011005860A2 (en) | 2009-07-07 | 2011-01-13 | Alnylam Pharmaceuticals, Inc. | 5' phosphate mimics |
| WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
| AU2012328680A1 (en) | 2011-10-25 | 2014-05-01 | Ionis Pharmaceuticals, Inc. | Antisense modulation of GCCR expression |
| CN113057959B (zh) * | 2014-02-11 | 2024-07-16 | 阿尔尼拉姆医药品有限公司 | 己酮糖激酶（KHK）iRNA组合物及其使用方法 |
| AU2015330670B2 (en) * | 2014-10-10 | 2022-01-06 | Novo Nordisk Health Care Ag | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
| DK3569711T3 (da) * | 2014-12-15 | 2021-02-22 | Dicerna Pharmaceuticals Inc | Ligandmodificerede dobbeltstrengede nukleinsyrer |
| HUE059718T2 (hu) | 2016-09-02 | 2022-12-28 | Dicerna Pharmaceuticals Inc | 4'-foszfát analógok és azokat tartalmazó oligonukleotidok |
| US20210332367A1 (en) * | 2018-09-18 | 2021-10-28 | Alnylam Pharmaceuticals, Inc. | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| AU2020358016A1 (en) * | 2019-10-02 | 2022-04-21 | Dicerna Pharmaceuticals, Inc. | Chemical modifications of small interfering RNA with minimal fluorine content |
| BR112022017822A2 (pt) * | 2020-03-06 | 2022-11-08 | Alnylam Pharmaceuticals Inc | Composições de irna de cetoexocinase (khk) e métodos de uso das mesmas |
| AU2022226098A1 (en) * | 2021-02-26 | 2023-08-24 | Alnylam Pharmaceuticals, Inc. | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
-
2022
- 2022-04-11 PE PE2023002847A patent/PE20250400A1/es unknown
- 2022-04-11 MX MX2023012048A patent/MX2023012048A/es unknown
- 2022-04-11 CR CR20230482A patent/CR20230482A/es unknown
- 2022-04-11 PH PH1/2023/552830A patent/PH12023552830A1/en unknown
- 2022-04-11 EP EP22719944.5A patent/EP4323518A2/en not_active Withdrawn
- 2022-04-11 BR BR112023017367A patent/BR112023017367A2/pt not_active Application Discontinuation
- 2022-04-11 CA CA3214439A patent/CA3214439A1/en active Pending
- 2022-04-11 AU AU2022256742A patent/AU2022256742A1/en not_active Withdrawn
- 2022-04-11 IL IL307315A patent/IL307315A/en unknown
- 2022-04-11 TW TW111113704A patent/TW202305135A/zh unknown
- 2022-04-11 US US17/717,174 patent/US20220340909A1/en not_active Abandoned
- 2022-04-11 CN CN202280027703.6A patent/CN117120612A/zh active Pending
- 2022-04-11 JP JP2023562314A patent/JP2024516356A/ja not_active Abandoned
- 2022-04-11 WO PCT/EP2022/059663 patent/WO2022218941A2/en not_active Ceased
- 2022-04-11 KR KR1020237038934A patent/KR20230170732A/ko active Pending
-
2023
- 2023-10-10 CL CL2023003017A patent/CL2023003017A1/es unknown
- 2023-10-11 EC ECSENADI202376906A patent/ECSP23076906A/es unknown
- 2023-10-11 DO DO2023000223A patent/DOP2023000223A/es unknown
- 2023-10-11 CO CONC2023/0013465A patent/CO2023013465A2/es unknown
- 2023-10-12 JO JOJO/P/2023/0250A patent/JOP20230250A1/ar unknown
-
2024
- 2024-04-22 US US18/641,868 patent/US20250092403A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202305135A (zh) | 2023-02-01 |
| AU2022256742A1 (en) | 2023-09-07 |
| JOP20230250A1 (ar) | 2023-10-12 |
| DOP2023000223A (es) | 2023-11-15 |
| ECSP23076906A (es) | 2023-11-30 |
| CL2023003017A1 (es) | 2024-05-03 |
| WO2022218941A2 (en) | 2022-10-20 |
| EP4323518A2 (en) | 2024-02-21 |
| BR112023017367A2 (pt) | 2023-12-12 |
| PH12023552830A1 (en) | 2024-05-20 |
| US20220340909A1 (en) | 2022-10-27 |
| CA3214439A1 (en) | 2022-10-20 |
| US20250092403A1 (en) | 2025-03-20 |
| PE20250400A1 (es) | 2025-02-11 |
| WO2022218941A3 (en) | 2023-02-23 |
| KR20230170732A (ko) | 2023-12-19 |
| CN117120612A (zh) | 2023-11-24 |
| JP2024516356A (ja) | 2024-04-15 |
| IL307315A (en) | 2023-11-01 |
| MX2023012048A (es) | 2023-10-23 |
| CO2023013465A2 (es) | 2023-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP23076906A (es) | Composiciones y métodos para inhibir cetohexoquinasa (khk) | |
| ECSP24035717A (es) | Compuestos de quinolina como inhibidores de kras | |
| ECSP22087539A (es) | Inhibidores de kras tricíclicos fusionados | |
| CO2022010547A2 (es) | Compuestos y usos de los mismos | |
| MX2017011269A (es) | Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos. | |
| UY40021A (es) | Inhibidores lisina acetiltransferasa 6a (kat6a) y usos de los mismos | |
| MX2021009673A (es) | Moduladores de ror-gamma. | |
| MX2019002750A (es) | Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer. | |
| CL2025000629A1 (es) | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos | |
| CO2019007409A2 (es) | Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos | |
| CL2023000371A1 (es) | Composiciones y métodos para inhibir la expresión de plp1. | |
| MX2022014924A (es) | Moduladores de il-17a. | |
| MX2021004566A (es) | Compuestos terapeuticos. | |
| UY32937A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119 | |
| CO2022018636A2 (es) | Moduladores de il-17a | |
| MX2022013396A (es) | Compuestos de tetrahidroisoquinolina como activadores de nrf2. | |
| MX2021003110A (es) | Agonistas del receptor x farnesoide y usos de los mismos. | |
| CL2023003363A1 (es) | Composiciones y métodos para inhibir la expresión del componente reductor 1 de amidoxima de mitocondria (marc1) | |
| MX2021000142A (es) | Composiciones y metodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas. | |
| CO2024017422A2 (es) | Composiciones y métodos para inhibir la expresión de serina proteasa transmembrana 6 (tmprss6) | |
| CO2024017526A2 (es) | Compuestos de degradación de wee1 y usos de los mismos | |
| MX2022013398A (es) | Compuestos de tetrahidroisoquinolina como activadores de nrf2. | |
| ECSP23091984A (es) | Compuestos y usos de estos | |
| CL2021000930A1 (es) | Piridazinas novedosas | |
| MX2021011334A (es) | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. |